Mayne Pharma Group (STU:HG6) Total Liabilities : €414.0 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Mayne Pharma Group Total Liabilities?

Mayne Pharma Group's Total Liabilities for the quarter that ended in Dec. 2024 was €414.0 Mil.

Mayne Pharma Group's quarterly Total Liabilities increased from Dec. 2023 (€371.27 Mil) to Jun. 2024 (€425.01 Mil) but then declined from Jun. 2024 (€425.01 Mil) to Dec. 2024 (€414.01 Mil).

Mayne Pharma Group's annual Total Liabilities declined from Jun. 2022 (€485.83 Mil) to Jun. 2023 (€379.73 Mil) but then increased from Jun. 2023 (€379.73 Mil) to Jun. 2024 (€425.01 Mil).

Mayne Pharma Group Total Liabilities Historical Data

The historical data trend for Mayne Pharma Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Total Liabilities Chart

Mayne Pharma Group Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

479.77

438.86

485.83

379.73

425.01

Mayne Pharma Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															442.95	379.73	371.27	425.01	414.01

Mayne Pharma Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mayne Pharma Group's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	193.658	+	(21.591	+	205.03
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	4.535	+	0.2	+	0)
	=	425.0

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	705.187	-	280.173
	=	425.0

Mayne Pharma Group's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	184.994	+	(1.698	+	219.642
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	7.679	+	0	+	0)
	=	414.0

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	683.883	-	269.87
	=	414.0

Mayne Pharma Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (STU:HG6) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

MAYNF:USA MYX:Australia

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Mayne Pharma Group Headlines

No Headlines